Ascorbic acid kills Epstein-Barr virus positive Burkitt lymphoma cells and Epstein-Barr virus transformed B-cells in vitro, but not in vivo

被引:15
|
作者
Shatzer, Amber N. [1 ]
Espey, Michael Graham [2 ]
Chavez, Mayra [1 ]
Tu, Hongbin [2 ]
Levine, Mark [2 ]
Cohen, Jeffrey I. [1 ]
机构
[1] NIAID, Med Virol Sect, Infect Dis Lab, Bethesda, MD 20892 USA
[2] NIDDK, Mol & Clin Nutr Sect, Digest Dis Branch, NIH, Bethesda, MD 20892 USA
关键词
Ascorbic acid; Epstein-Barr virus; Burkitt; lymphoma; reactive oxygen species; bortezomib; NF-KAPPA-B; GENE-EXPRESSION; CANCER-CELLS; VITAMIN-C; LYMPHOPROLIFERATIVE DISEASE; ACQUIRED IMMUNODEFICIENCY; NASOPHARYNGEAL CARCINOMA; GASTRIC-CARCINOMA; HYDROGEN-PEROXIDE; HODGKINS-DISEASE;
D O I
10.3109/10428194.2012.739686
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Ascorbic acid has been shown to kill various cancer cell lines at pharmacologic concentrations. We found that Epstein-Barr virus (EBV)-positive Burkitt lymphoma (BL) cells were more susceptible to ascorbic acid-induced cell killing than EBV-negative BL cells or EBV-transformed lymphoblastoid cells (LCLs). Ascorbic acid did not induce apoptosis in any of the tested cells but did induce the production of reactive oxygen species and cell death. Previously, we showed that bortezomib, a proteasome inhibitor, induces cell death in LCLs and EBV-positive BL cells. We found that ascorbic acid is strongly antagonistic for bortezomib-induced cell death in LCLs and EBV-positive BL cells. Finally, ascorbic acid did not prolong survival of severe combined immunodefiency mice inoculated with LCLs either intraperitoneally or subcutaneously. Thus, while ascorbic acid was highly effective at killing EBV-positive BL cells and LCLs in vitro, it antagonized cell killing by bortezomib and was ineffective in an animal model.
引用
收藏
页码:1069 / 1078
页数:10
相关论文
共 50 条
  • [1] Epstein-Barr virus and Burkitt lymphoma
    Rowe, Martin
    Fitzsimmons, Leah
    Bell, Andrew I.
    CHINESE JOURNAL OF CANCER, 2014, 33 (12) : 609 - 619
  • [2] Epstein-Barr virus and Burkitt lymphoma
    Martin Rowe
    Leah Fitzsimmons
    Andrew I Bell
    Chinese Journal of Cancer, 2014, 33 (12) : 609 - 619
  • [3] Epstein-Barr virus and Burkitt lymphoma
    Brady, G.
    MacArthur, G. J.
    Farrell, P. J.
    JOURNAL OF CLINICAL PATHOLOGY, 2007, 60 (12) : 1397 - 1402
  • [4] Epstein-Barr virus and Burkitt lymphoma
    Brady, G.
    MacArthur, G. J.
    Farrell, P. J.
    POSTGRADUATE MEDICAL JOURNAL, 2008, 84 (993) : 372 - 377
  • [5] EPSTEIN-BARR VIRUS AND BURKITT-LYMPHOMA
    不详
    LANCET, 1978, 2 (8089): : 561 - 561
  • [6] Burkitt lymphoma and the discovery of Epstein-Barr virus
    Epstein, Anthony
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 156 (06) : 777 - 779
  • [7] Cytotoxic drug sensitivity of Epstein-Barr virus transformed lymphoblastoid B-cells
    Markasz, L.
    Stuber, G.
    Flaberg, E.
    Jernberg, A. Gustafsson
    Eksborg, S.
    Olah, E.
    Skribek, H.
    Szekely, L.
    BLOOD REVIEWS, 2007, 21 : S98 - S99
  • [8] Cytotoxic drug sensitivity of Epstein-Barr virus transformed lymphoblastoid B-cells
    Markasz, Laszlo
    Stuber, Gyorgy
    Flaberg, Emilie
    Jernberg, Asa Gustafsson
    Eksborg, Staffan
    Olah, Eva
    Skribek, Henriette
    Szekely, Laszlo
    BMC CANCER, 2006, 6 (1)
  • [9] ESTIMATION OF B-CELLS TRANSFORMED BY EPSTEIN-BARR VIRUS IN PATIENTS WITH CONGENITAL AGAMMAGLOBULINEMIA
    TSUCHIYA, S
    NAKAE, S
    KONNO, T
    TADA, K
    ONO, Y
    TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, 1981, 135 (04): : 379 - 385
  • [10] Cytotoxic drug sensitivity of Epstein-Barr virus transformed lymphoblastoid B-cells
    Laszlo Markasz
    György Stuber
    Emilie Flaberg
    Åsa Gustafsson Jernberg
    Staffan Eksborg
    Eva Olah
    Henriette Skribek
    Laszlo Szekely
    BMC Cancer, 6